291 SUPEROVULATORY RESPONSE IN BEEF CATTLE TREATED DURING THE FIRST FOLLICULAR WAVE FOLLOWING SYNCHRONIZATION OF OVULATION WITH A PROGESTIN DEVICE AND GnRH

2009 ◽  
Vol 21 (1) ◽  
pp. 242 ◽  
Author(s):  
D. Carballo Guerrero ◽  
A. Tríbulo ◽  
R. Tríbulo ◽  
H. Tríbulo ◽  
G. A. Bó
Keyword(s):  
Animal Health ◽  
Treatment Protocol ◽  
Crossover Design ◽  
Control Group ◽  
Embryo Production ◽  
Treatment Protocols ◽  
Follicular Wave ◽  
Group 2 ◽  
Student’S T ◽  
Group 1

Although we have previously shown that superstimulation during the first follicular wave resulted in a successful response (Carballo Guerrero D et al. 2007 Reprod. Fertil. Dev. 20, 226), the protocol required many interventions that could influence its application in the field. Therefore, two studies were designed to simplify the superstimulation treatment protocol. Experiment 1 was designed to determine whether it was necessary to remove the progesterone releasing device during the superstimulation protocol. Angus cows (n = 37) were superstimulated by two treatments in a crossover design. Cows in Group 1 (control) received a progesterone releasing device (Cue-Mate, Bioniche Animal Health, Belleville, ON, Canada) along with 0.150 mg D cloprostenol (PGF, Bioprost-D, Biotay, Argentina) IM, at random stages of the estrous cycle. Five days later, a second PGF was injected and Cue-Mates were removed, followed by GnRH (0.050 mg Lecirelina, Biosin-OV, Biotay) 36 h later; ovulation was expected to occur 30 to 36 h later. On Day 0 (36 h after GnRH) donors received a new Cue-Mate and superstimulation treatment was initiated with a total dose of 400 mg NIH-FSH-P1 of Folltropin-V (FSH, Bioniche Animal Health) in twice daily decreasing doses over 5 days. PGF was injected with the last two FSH injections and Cue-Mates were removed with the last FSH injection. Cows in Group 2 were treated similarly to those in the control group, except that Cue-mate devices were not replaced and remained in place for 13 days (i.e. Cue-mates were removed with the last FSH and PGF injection). All donors received 12.5 mg pLH (Lutropin-V, Bioniche Animal Health) 24 h after Cue-Mate removal and were AI 12 and 24 h later. Embryos were collected 7 days after pLH. Means were compared between groups by Student’s t-test. Superovulatory response and embryo production did not differ between groups. Mean (± SEM) number of ova/embryos collected and transferable embryos were 8.2 ± 1.0 and 4.1 ± 0.6 v. 9.8 ± 0.9 and 5.7 ± 0.7 for Groups 1 and 2, respectively (P > 0.2). Experiment 2 was designed to evaluate the effect of giving FSH for 4 v. 5 days. Simmental (n = 18) and Angus (n = 6) cows were superstimulated by the two treatment protocols in a crossover design. Cows in both groups were treated similarly to those in Group 2 in Experiment 1 (i.e. Cue-Mates were not replaced during treatment). Cows in Group 1 (control) received FSH over 5 days (as in Group 2 of Experiment 1); while those in Group 2 received the same dosage of FSH, but given in twice daily decreasing doses over 4 days (Cue-Mates were removed with the last FSH and PGF injections). Superovulatory response and embryo production did not differ among groups. Mean (± SEM) number of ova/embryos collected and transferable embryos were 13.5 ± 2.4 and 6.6 ± 1.1 v. 12.0 ± 1.9 and 5.8 ± 1.0 for Groups 1 and 2, respectively (P > 0.6). In conclusion, superstimulation of cattle at the time of emergence of the first follicular wave after ovulation results in an acceptable superovulatory response and all treatments evaluated were user-friendly and equally efficient.

351 A COMPARISON OF 2 APPROACHES FOR THE USE OF GnRH TO SYNCHRONIZE FOLLICLE WAVE EMERGENCE FOR SUPEROVULATION

2015 ◽  
Vol 27 (1) ◽  
pp. 263 ◽  
Author(s):  
R. H. Hinshaw ◽  
M. L. Switzer ◽  
R. J. Mapletoft ◽  
G. A. Bó
Keyword(s):  
Mixed Models ◽  
Animal Health ◽  
Treatment Protocol ◽  
Prostaglandin F2α ◽  
Random Variable ◽  
Crossover Design ◽  
Dominant Follicle ◽  
Follicular Wave ◽  
Group 2 ◽  
Group 1

Although oestradiol has been used successfully to synchronize follicle wave emergence for superovulation, it cannot be used in many countries. Attention has turned to alternatives, including the use of GnRH to induce ovulation of a dominant follicle, which will be followed by emergence of a new follicular wave in 1 to 2 days. However, GnRH synchronizes follicular wave emergence only when it induces ovulation and administration of GnRH at random stages of the oestrous cycle results in ovulation in less than 60% of animals. The objective of the study was to compare superovulatory response and ova/embryo production following synchronization of follicle wave emergence for superovulation with GnRH administered 2 days after insertion of a progestin device, with a protocol in which GnRH is administered 7 days after administration of prostaglandin F2α and a progestin device. Beef donors of various breeds were placed at random into 1 of 2 groups and superstimulated by replicate so that one cow in each group had ova/embryos collected on the same day. Sixty-six superstimulations were performed in this study; 26 were performed in 13 donors that were superstimulated twice in a crossover design, and 40 donors were superstimulated once (i.e. 20 donors in each treatment group). Cows in group 1 received CIDR devices (Zoetis Animal Health, USA) on Day –2 and 100 μg of GnRH (Cystorelin, Merial USA) on Day 0; FSH treatments were initiated on Day 2 with 288 mg of Folltropin-V (Vetoquinol, Canada) given in twice-daily decreasing doses for 4 days. Prostaglandin F2α (PGF; 35 mg dinoprost, Lutalyse, Zoetis) was given with the last 2 injections of Folltropin-V and CIDR were removed with the last Folltropin-V administration (i.e. Day 6). Donors received a second GnRH at the onset of oestrus and were AI 8 and 20 h later. Donors that were still in standing oestrus at the second AI were AI again at 30 h. Ova/embryo collections were done on Day 14 and embryos were classified according to the IETS manual. Cows in group 2 received an injection of PGF and a CIDR on Day –7 and 100 μg of GnRH on Day 0; FSH treatments were initiated on Day 2 and the remainder of the treatment protocol was as in group 1. Data (total ova/embryos collected and transferable embryos) were analysed by ANOVA for mixed models, using treatment as a fixed variable and cow (i.d.) as a random variable. The group 1 cows produced a mean (± s.e.m.) of 18.6 ± 1.9 total ova/embryos of which 12.7 ± 1.5 were of transferable quality (7.2 ± 1.3 grade 1). Cows in group 2 produced a mean (± s.e.m.) of 19.5 ± 1.7 total ova/embryos, of which 14.8 ± 1.5 were of transferable quality (8.9 ± 1.2 grade 1). Although 2 more transferable embryos were obtained in group 2, differences were not significant (P > 0.3). At the same time as this experiment was done, 214 other cows were superstimulated in this practice, yielding an average of 7.9 transferable embryos per donor. Results suggest that both approaches are efficacious for the superstimulation of beef cows.Special thanks to Vetoquinol/Bioniche Animal Health, USA for support.

404 SUPEROVULATORY RESPONSE IN BEEF DONORS TREATED DURING THE FIRST FOLLICULAR WAVE OR FOUR DAYS AFTER PROGESTERONE AND ESTRADIOL ADMINISTRATION

2010 ◽  
Vol 22 (1) ◽  
pp. 358 ◽  
Author(s):  
D. Carballo Guerrero ◽  
A. Tríbulo ◽  
R. Tríbulo ◽  
H. Tríbulo ◽  
G. A. Bó
Keyword(s):  
Estrous Cycle ◽  
Animal Health ◽  
Estradiol Benzoate ◽  
Control Group ◽  
Wave Groups ◽  
Follicular Wave ◽  
Estrus Detection ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Although we have previously shown that ovarian superstimulation during the first follicular wave resulted in a successful response (Carballo Guerrero D et al. 2009 Reprod. Fertil. 21, 242), the current protocol needs to be optimized in order to be used in the field. Therefore, an experiment was designed to simplify this treatment and to compare it with the traditional superstimulation protocol using progesterone and estradiol. Simmental cows (n = 14) were subjected to 3 superstimulation treatments (2 first wave groups and 1 control group) in a crossover design (i.e. all cows received the 3 treatments and all treatments were represented on each collection day). Cows in Group 1 received a progesterone-releasing device (Cue-Mate®, Bioniche Animal Health, Belleville, Ontario, Canada) along with 0.150 mg of D + cloprostenol (PGF; Bioprost-D®, Biotay, Buenos Aires, Argentina) at random stages of the estrous cycle. A second PGF was injected 5 days after Cue-Mate® insertion, followed by GnRH (0.050 mg of lecirelin; Biosin-OV®, Biotay) 36 h later (i.e. 7 days after Cue-Mate® insertion). Based on previous studies, ovulation was expected to occur 30 to 36 h later. Therefore, superstimulation treatments were initiated 36 h after GnRH (Day 0), with a total dose of 400 mg NIH-FSH-P1 of Folltropin®-V (Bioniche Animal Health) in twice-daily decreasing doses over 4 days. Prostaglandin was administered with the last 2 Folltropin®-V injections and Cue-Mate® devices were removed with the last Folltropin®-V injection. Cows received 12.5 mg of porcine LH (Lutropin®-V, Bioniche Animal Health) 24 h after Cue-Mate® removal and were AI 12 and 24 h later. Ova/embryos were collected 7 days after porcine LH and evaluated following IETS recommendations. Cows in Group 2 were treated similarly to those in the Group 1, except they did not receive the second PGF injection 5 days after Cue-Mate® insertion (thus eliminating the need to handle animals on that day). Finally, cows in Group 3 [estradiol benzoate (EB)+P4 control group] received a Cue-Mate® plus 2.5 mg of EB (Bioestradiol®, Biotay) and 50 mg of progesterone (P4; Lab., Rio de Janeiro, Argentina) at random stages of their estrous cycle. Superstimulation treatments were initiated 4 days later (Day 0) following the same protocol used in Group 1. Data were transformed to square root and analyzed by ANOVA. Mean (± SEM) numbers of ova/embryos collected, fertilized ova, and transferable embryos did not differ among groups (12.9 ± 2.0, 9.8 ± 1.7, and 6.6 ± 1.2; 11.5 ± 1.7, 9.3 ± 1.5, and 7.7 ± 1.6; and 14.5 ± 2.8, 9.4 ± 2.3, and 6.8 ± 1.7 for Groups 1, 2, and 3, respectively). In conclusion, data demonstrated that superstimulation during the first follicular wave can be successfully used in groups of randomly cycling donors without the need for estrus detection or estradiol to synchronize follicular wave emergence. The protocol is easy to follow and embryo production is comparable to that of the estradiol and progesterone protocol.

225 ADDITION OF EQUINE CHORIONIC GONADOTROPIN TO A TRADITIONAL FOLLICLE STIMULATING HORMONE PROTOCOL FOR SUPEROVULATION OF BOS TAURUS BEEF COWS

2012 ◽  
Vol 24 (1) ◽  
pp. 224 ◽  
Author(s):  
R. L. Davis ◽  
A. Arteaga ◽  
J. F. Hasler
Keyword(s):  
Treatment Group ◽  
South America ◽  
Bos Taurus ◽  
Animal Health ◽  
Bos Indicus ◽  
Treatment Protocol ◽  
Beef Cows ◽  
High Response Rate ◽  
Control Group ◽  
Embryo Production

This study examined the superovulatory responses of Bos taurus beef cows maintained in a commercial embryo transfer facility. Donors were superovulated 1 to 3 times each with either a traditional 8 injection FSH protocol (controls, n = 126) or 6 injections of FSH with the seventh or eighth FSH treatments replaced by 2 injections of eCG (treatment, n = 134). During the 5-month study, 132 donors were alternatively assigned to a control or treatment group for a single superovulation and an additional 62 animals were superovulated 2 (n = 58) or 3 times (n = 4) in a crossover design. Although 14 beef breeds were represented in the study, 87% of the cows were Angus, Red Angus, Polled Hereford, or Charolais. All donors were synchronized on Day 0 with a CIDR, 5 mg of oestradiol-17β and 100 mg of progesterone. Starting on Day 4 (p.m.), controls were injected twice daily for 4 days with descending doses of porcine FSH (Folltropin-V®, Bioniche Animal Health, Belleville, Ontario, Canada). Cows received 750 μg of cloprostenol (Estrumate®, Intervet Schering-Plough, Summit, NJ, USA) at the seventh FSH injection and the CIDR was removed at the eighth FSH injection. Based on previous experience with specific, individual animals, total FSH dose per donor ranged from 240 to 400 mg. However, 74% of treatments involved 380 mg for controls and 310 mg for treated donors that received eCG. In addition, donors that were superovulated more than once received the same FSH dose in the crossover, treatment-control design. In the treatment group, 200 IU of eCG (Pregnecol™ 6000, Bioniche Animal Health) was substituted for the seventh and eighth FSH injections. Inseminations were conducted on a timed AI basis, with one unit of semen 32 h and a second 48 h following CIDR removal. Results were analysed by ANOVA as shown in Table 1. Although more ova/embryos and unfertilized ova (UFO) were recovered in the control group, the control and treatment groups did not differ in the number of grade 1, 2, or 3 embryos or in the number of degenerate embryos. Previous superovulation studies in South America using eCG to replace the last 2 injections of FSH resulted in more total ova/embryos in Nelore cows but not heifers and in more embryos in Brangus and Sindhi cows. The mean embryo production for the control cows in this study was high and the addition of eCG in the protocol did not improve embryo production. Failure of eCG to increase the number of embryos for Bos taurus cows in this study compared with previous studies may be due to differences with Bos taurus versus Bos indicus breeds or differences in management factors between Canada and South America. The high response rate in the controls may also have contributed to the failure of any advantage of adding eCG to the treatment protocol. Table 1.Mean numbers (± SEM) of ova and embryos recovered from Bos taurus females superovulated with 2 different protocols

196 Embryo production using follicle-stimulating hormone (FSH) or FSH+equine chorionic gonadotropin in beef donors

2019 ◽  
Vol 31 (1) ◽  
pp. 223
Author(s):  
J. L. Barajas ◽  
A. Cedeño ◽  
S. Andrada ◽  
J. A. Ortega ◽  
J. M. Oviedo ◽  
...  
Keyword(s):  
Single Dose ◽  
Body Condition Score ◽  
Crossover Design ◽  
Control Group ◽  
Santa Fe ◽  
Embryo Production ◽  
Condition Score ◽  
Group 2 ◽  
Equine Chorionic Gonadotropin ◽  
Dose 300Mg

The objective of the present study was to evaluate the superovulatory response and embryo production in beef donors using 8 twice-daily injections of FSH or an alternative protocol in which the last 4 FSH injections were replaced with a single injection of eCG. In Exp. 1, 12 mature Bonsmara donor cows, with a body condition score between 3 and 4 (1 to 5 scale) were superstimulated twice every 46 days in a crossover design (i.e. in each experiment all cows received 2 treatments and the 2 treatments were equally represented in each replicate). On Day 0 a.m., all donors received an intravaginal device with 1.2g of progesterone (Diprogest 1200®, Zoovet, Santa Fe, Argentina), along with 50mg of progesterone i.m (Progestar®, Zoetis, Buenos Aires, Argentina) and 5mg of oestradiol-17β (17βOestradiol®, Rio de Janeiro, Argentina) IM. On Day 4 a.m., the superstimulatory treatments were initiated and donors in the control group received 8 applications of FSH (Folltropin-V, Vetoquinol, Lure, France), IM (total dose: 300mg NIH-FSH-P1) in a twice-daily decreasing dosage schedule over 4 days (i.e. 60, 60, 50, 50, 30, 30, 10, and 10mg, respectively). Donors in the FSH+800 eCG group received only the first 4 applications of FSH (i.e. 60, 60, 50 and 50mg, respectively) and on Day 6 a.m. they received 800IU of eCG (Novormón®, Zoetis) IM in a single dose. All donors received 500μg of cloprostenol (Ciclase DL®, Zoetis) IM on Day 6 a.m. and p.m., and the intravaginal devices were removed on Day 7 a.m. All cows also received 100μg of gonadorelin acetate (GnRH, Gonasyn gdr, Zoetis) on Day 8 a.m. and were inseminated with frozen-thawed semen from 2 bulls 12 and 24h later. On Day 15, ova/embryos were collected and evaluated according to the IETS standards. The data were analysed by GLMM (Infostat, 2018). In Exp 2., 18 Bonsmara donors with similar conditions as those in Exp. 1 were superovulated twice in a crossover design. Cows in both groups received similar treatments to those in the FSH+eCG treatment of Exp. 1, except that the total dosage of FSH was 200mg (i.e. 60, 60, 40, and 40mg, respectively) and the eCG given on Day 6 a.m. was either 600IU (group 1) or 800IU (group 2). In Exp 1., the FSH (control) group had a higher (P<0.01) number of fertilized oocytes, but there were no differences in the other end points evaluated (Table 1). In Exp. 2, no differences were found between FSH+800 eCG and FSH+600 eCG groups in any of the parameters evaluated. In conclusion, the replacement of the last 4 injections of FSH by a single dose of eCG decreases the number of treatments required in a superovulation program without negatively affecting the production of transferable embryos. Table 1.Embryo production (means±s.e.m.) in Bonsmara donors treated with FSH or FSH+eCG

234 HORMONAL FOLLICLE STIMULATION IN HOLSTEIN COWS FOR IN VITRO EMBRYO PRODUCTION USING SPERM SORTED BY FLOW CYTOMETRY

2016 ◽  
Vol 28 (2) ◽  
pp. 248 ◽  
Author(s):  
L. Ferré ◽  
Y. Bogliotti ◽  
J. Chitwood ◽  
M. Kjelland ◽  
P. Ross
Keyword(s):  
Transvaginal Ultrasound ◽  
Prostaglandin F2α ◽  
Holstein Cows ◽  
Control Group ◽  
Hatching Rate ◽  
Embryo Production ◽  
In Vitro Embryo Production ◽  
Group 2 ◽  
Group 1

Transvaginal ultrasound needle-guided ovum pick-up (OPU) and in vitro embryo production (IVP) offer a reliable alternative to conventional embryo transfer to produce offspring. The success of OPU/IVP greatly depends on the number and quality of retrieved oocytes. The aim of this study was to compare OPU/IVP performance from stimulated Holstein cows. Holstein (Bos taurus) >8-year-old pluriparous open dry cows (n = 28) were used for OPU as oocyte donors. Follicular waves in all groups were synchronized by gonadotropin-releasing hormone (GnRH), prostaglandin F2α (PGF), and CIDR administrated on Day 0, followed by stimulation treatments 48 h later. No pre-synch was used. Total hormone dosage were administrated as follows: Group 1: pFSH = 180 mg (Folltropin, Bioniche, Belleville, ON, Canada; n = 7), Group 2: pFSH/LH = 500 IU (Pluset, Calier, Barcelona, Spain; n = 7), Group 3: eCG = 1500 IU (eCG, Biogénesis-Bagó, Buenos Aires, Argentina; n = 7) and Group 4: Control (n = 7), no stimulation. All injections were performed intramuscularly (i.m.) twice a day, during three days. OPU was performed 48 (Group 1) or 24 h (Group 2 and 3) after the last injection. The control group received saline solution i.m. Follicles were classified according to diameter in 4 categories: small (2–5 mm); medium (6–9 mm); large (10–14 mm) and extra large (>15 mm). A Mindray DP-30 Vet (Mindray Medical, Shenzhen, China) was equipped with a micro-convex transducer 5.0- to 8.5-MHz probe along with a disposable 21G needle. The OPU flow rate was 15 mL min–1. Retrieved oocytes were classified according to IETS guidelines as viable (grade 1 + 2) and non-viable (grade 3 + 4). The IVP protocol was according to that in Reprod. Fertil. Devel. (2004, 16, 253). Fertilization (Day 0) was carried out using female sex-sorted semen selected with a discontinuous density gradient (PureSperm, Nidacon, Mölndal, Sweden) and diluted to 1 × 106 sperm mL–1. ANOVA was used for comparisons of mean values and a chi-squared test was used for proportions. Results are presented in the Table 1. In conclusion, pFSH stimulation before ovum pick-up in Holstein cows increased the number of collected and viable oocytes, cleavage, embryo development, and hatching rates in comparison to other follicle stimulation hormones and non-stimulation. A cost-benefit analysis of these methods could be valuable in order to inform whether or not a stimulation protocol is necessary for a commercial IVP operation. Table 1.Numbers of follicles, collected and viable oocytes, cleavage rate, blastocysts and hatching rate

INFLUENCE OF THE DURABLE APPLICATION OF PROTONIC PUMP INHIBITORS ON CYTOKINE CONCENTRATION IN RAT BLOOD SERUM

2021 ◽  
Vol 74 (7) ◽  
pp. 1575-1580
Author(s):  
Serhii V. Pylypenko ◽  
Andrii A. Koval ◽  
Makarchuk V. Viktoria ◽  
Kostiantyn F. Chub
Keyword(s):  
Blood Serum ◽  
Inflammatory Cytokines ◽  
Male Rats ◽  
Control Group ◽  
Hcl Secretion ◽  
Group 3 ◽  
Anti Inflammatory ◽  
Group 2 ◽  
Student’S T ◽  
Group 1

The aim: Of the work was to determine the content of pro- and anti-inflammatory cytokines in the blood serum of the control group rats and after 28 days of inhibiting HCl secretion in the stomach by proton pump blockers “Omeprazole” and “Pantoprazole”. Materials and methods: The studies were performed on 30 white non-linear male rats weighing 160-180 g, divided into three groups with 10 animals in each. The control (group 1) were injected intraperitoneally with water for injections within 28 days once a day. Group 2 was administered omeprazole. Group 3 was administered pantoprazole. The concentration of cytokines in the blood serum of rats was determined by the enzyme immunoassay method. For statistic data processing, Student’s t-criterion for independent samples was applied. Results: After prolonged administration of omeprazole and pantoprazole, the blood serum concentrations of IFNγ, TNFα, IL-1 in rats increased by 58.5% and 3.41%, 73.3% and 48.4%, 80.2% and 40.8%, respectively, and IL-12B 40p decreased by 36.6% when using omeprazole and was almost indistinguishable from the control values when pantoprazole was administered. With administration of omeprazole, IL-4 concentration decreased by 39.8% and that of pantoprazole increased by 3.86% compared to the control. Administration of omeprazole and pantoprazole did not affect IL-6 concentration. Conclusion: Inhibition of hydrochloric acid secretion in the stomach of rats for 28 days using omeprazole and pantoprazole led to an imbalance between pro- and anti-inflammatory cytokines. The adverse effect of pantoprazole was less pronounced than that of omeprazole.

scholarly journals Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt

Antibiotics ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1278
Author(s):  
Ragaey A. Eid ◽  
Marwa O. Elgendy ◽  
Ahmed O. El-Gendy ◽  
Sara O. Elgendy ◽  
Lassaad Belbahri ◽  
...  
Keyword(s):  
Recovery Time ◽  
Age Groups ◽  
Treatment Protocol ◽  
Control Group ◽  
Management Protocol ◽  
Ic50 Values ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study. Out of them, 260 patients were treated with cefepime or ceftazidime, with the addition of steroids to the treatment. Patients were divided into three groups: Group 1: patients treated with cefepime (124 patients); Group 2: patients treated with ceftazidime (136 patients); Group 3 (control group): patients treated according to the WHO guidelines and the Egyptian COVID-19 management protocol (110 patients)/ Each group was classified into three age groups: 18–30, 31–60, and >60 years. The dose of either cefepime or ceftazidime was 1000 mg twice daily for five days. Eight milligrams of dexamethasone were used as the steroidal drug. Careful follow-ups for the patients were carried out. In vitro and in silico Mpro enzyme assays were performed to investigate the antiviral potential of both antibiotics. The mean recovery time for Group 1 was 12 days, for Group 2 was 13 days, and for Group 3 (control) was 19 days. No deaths were recorded, and all patients were recovered without any complications. For Group 1, the recovery time was 10, 12, and 16 days for the age groups 18–30, 30–60, and >60 years, respectively. For Group 2, the recovery time was 11, 13, and 15 days for the age groups 18–30, 30–60, and >60 years, respectively. For Group 3 (control), the recovery time was 15, 16, and 17 days for the age groups 18–30, 30–60, and >60 years, respectively. Both ceftazidime and cefepime showed very good inhibitory activity towards SARS CoV-2′s Mpro, with IC50 values of 1.81 µM and 8.53 µM, respectively. In conclusion, ceftazidime and cefepime are efficient for the management of moderate and severe cases of COVID-19 due to their potential anti-SARS CoV-2 activity and low side effects, and, hence, the currently used complex multidrug treatment protocol can be replaced by the simpler one proposed in this study.

RISKS OF ANEMIA DEVELOPMENT IN DONORS ACCORDING TO INHERITED PREDISPOSITION AND REGULARITY OF BLOOD DONATION

2020 ◽  
pp. 72-83
Author(s):  
I.M. Vorotnikov ◽  
V.A. Razin ◽  
I.M. Lamzin ◽  
M.N. Sokolova ◽  
M.E. Khapman ◽  
...  
Keyword(s):  
Blood Donors ◽  
Blood Donation ◽  
Hla Antigens ◽  
Hla Typing ◽  
Main Role ◽  
Inherited Predisposition ◽  
Group 2 ◽  
Student’S T ◽  
A Prospective Study ◽  
Group 1

Anemia is one of the most common complications of blood donation. Thus, the objective of the paper was to assess the risks of anemia development in donors according to the regularity of donation and inherited predisposition. Materials and Methods. The authors carried out a prospective study, which included 241 blood donors, using random sampling and case-control techniques. Depending on blood donation frequency, the donors were divided into 2 groups: Group 1 consisted of 122 people (51.5 %) frequently donating blood; Group 2 included 119 people (48. 5 %) rarely donating blood. We studied the initial indicators of a general blood test and the same indicators a year after the first blood donation. Additionally, we performed HLA typing of donors. Statistica v. 8.0 software package (Stat Soft Inc., USA) was used for statistical analysis. To compare two independent samples, we used a nonparametric Mann-Whitney U-test and a parametric Student’s t-test (depending on the type of distribution). To assess anemia risks, the odds ratio was calculated. Results. One year after the first blood donation, anemia was diagnosed in 13 people (10.6 %) in Group 1 and in 7 people (5.9 %) in Group 2 (p=0.179). A11 and B7 HLA antigens did not increase anemia risks in group 1 (OS=1.257 (95 % CI 0.318–4.973) and OS=0.240 (95 % CI 0.051–1.134, respectively). HLA-antigens A11 and B7 did not increase anemia risks in Group 1 (OR=1.257 (95 % CI 0.318-4.973) and OR=0.240 (95 % CI 0.051–1.134), respectively). In group 2, antigen-A11 was also an insignificant factor (OS=2.902 (95 % CI 0.606-13.889)) for anemia development. Whereas, antigen-B7 increased anemia risks by 14 times (OS=14.364 (95 % CI 1.644-124.011)). Conclusion. In rare blood donors, it is the genetic factor that plays the main role in anemia development. High prevalence rates of anemia in frequent blood donors are probably determined by other factors. Keywords: anemia, blood donors, HLA typing. Механизмы развития анемий и факторы, их индуцирующие, остаются до конца не изученными. Целью исследования стало изучение риска развития анемии у доноров крови в зависимости от частоты донации и наличия наследственной предрасположенности к развитию анемии. Материалы и методы. Проведено проспективное исследование, выполненное методами случайной выборки и «случай-контроль», в которое вошел 241 донор крови. В зависимости от частоты сдачи доноры были поделены на 2 группы: группу 1 составили 122 чел. (51,5 %), часто сдающие кровь; группу 2 – 119 чел. (48,5 %), редко сдающих кровь. Изучались исходные показатели общего анализа крови и через год от начала донации. Дополнительно проводилось HLA-типирование доноров. Статистический анализ осуществлялся с применением программы Statistica v. 8.0 (Stat Soft Inc., США). Для сравнения двух независимых выборок использовался непараметрический U-критерий Манна–Уитни и параметрический t-критерий Стьюдента (в зависимости от типа распределения). Для оценки риска возникновения анемии рассчитывалось отношение шансов. Результаты. Через год с момента первой сдачи крови в группе 1 выявлено 13 чел. (10,6 %) с анемией, в группе 2 – 7 чел. (5,9 %) (р=0,179). Наличие HLA-антигенов А11 и B7 не повышало риск развития анемии в группе 1 (ОШ=1,257 (95 % ДИ 0,318–4,973) и ОШ=0,240 (95 % ДИ 0,051–1,134 соответственно). В группе 2 наличие гена А11 также являлось незначимым фактором (ОШ=2,902 (95 % ДИ 0,606–13,889), присутствие гена В7 в 14 раз повышало риск развития анемии (ОШ=14,364 (95 % ДИ 1,664–124,011). Выводы. Высокий риск развития анемии у редко сдающих кровь доноров обусловливается генетическими факторами. Высокая распространённость анемии у часто сдающих кровь доноров, вероятно, определяется другими факторами. Ключевые слова: анемия, доноры крови, HLA-типирование.

Antiurolithiatic effect of Cymbopogon Proximus, Alhagi Maurorum, on Sulfadimidine induced urolithiasis in male New Zealand rabbits

2019 ◽  
Vol 20 (1) ◽  
pp. 12-18
Author(s):  
Sameh El-Nabtity
Keyword(s):  
New Zealand ◽  
Intramuscular Injection ◽  
Negative Control Group ◽  
Negative Control ◽  
Control Group ◽  
Aqueous Extracts ◽  
Blood And Urine Samples ◽  
Group 2 ◽  
New Zealand Rabbits ◽  
Group 1

The present study aimed to investigate the prophylactic effect of Cymbopogon proximus and Alhagi maurorum on Sulfadimidine induced urolithiasis in rabbits . Thirty New Zealand male rabbits were allocated into six equal groups (each of five): Group (1) was used as a negative control. Group(2) were administered sulfadimidine (200mg/kg) by intramuscular injection.Groups(3) and (4) were administered sulfadimidine(200mg/kg) by intramuscular injection and 330mg/kg of Cymbopogon proximus alcoholic and aqueous extracts respectively orally.Groups(5) and (6) were administered sulfadimidine(200mg/kg) by intramuscular injection and 400mg/kg of Alhagi maurorum alcoholic and aqueous extracts respectively orally. The period of experiment was 10 days. Blood and urine samples were collected from rabbits on the 10th day. The results recorded a significant decrease in serum creatinine, urea, uric acid and crystalluria in Cymbopogon proximus and Alhagi maurorum groups compared to sulfadimidine treated group.We conclude that Cymbopogon proximus and Alhagi maurorum have a nephroprotective and antiurolithiatic effects against sulfadimidine induced crystalluria.

Influence of Removable Denture Cleaning Agents on Adhesion of Oral Pathogenic Microflora In Vitro: A Randomized Controlled Trial

2021 ◽  
Vol 14 (1) ◽  
pp. 656-664
Author(s):  
I.R. Volchkova ◽  
A.V. Yumashev ◽  
V.V. Borisov ◽  
V.I. Doroshina ◽  
E.A. Kristal ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Candida Albicans ◽  
Test Group ◽  
Control Group ◽  
Removable Dental Prostheses ◽  
Removable Denture ◽  
Group 2 ◽  
Adhesion Index ◽  
Group 1

Introduction: Removable dentures are used by 20% of the population. These may be accompanied by denture stomatitis in 15-70% of patients. The choice of the optimal cleansing agent for removable dental prostheses is of high significance. Aim: The aim of our research was to study the influence of removable denture cleansing products on the adhesion of microorganisms and yeast. Materials and Methods: We manufactured 144 specimens of standardized round shape with a diameter of 10 mm from 4 types of modern polymeric materials used by prosthetic dentistry to produce removable dentures, 12 specimens of each material were placed into suspensions of bacterial cultures of Staphylococcus aureus, Escherichia coli, Candida albicans, then into “ClearaSept” (Test group 1), “Рrotefix active cleanser” (Test group 2), saline solution (Control group), followed by nutrient media. The adhesion index was calculated and analyzed. Results: There was no reliable lowering of adhesion index of Staphylococcus Aureus to all materials detected in Test group 1 (U=6, p>0.05 for Bio XS; U=8, p>0.05 for Dental D, Denotokeep Peek, Vertex Rapid Simplified). In Test group 2, the adhesion index of Staphylococcus Aureus reliably decreased to all materials compared to the Control group (U=0, p≤0.01). The adhesion index of Candida albicans and Escherichia coli to all materials in Test group 1 had a minor to moderate reliable reduction compared to the Control group (U=0, p≤0.01). Test group 2 showed a significant reliable decrease in Candida albicans and Escherichia coli adhesion index to all materials in comparison with the Control group (U=0, p≤0.01). Conclusion: The research showed an unreliable or minor and moderate reliable decrease in microorganisms adhesion index depending on the microorganism species after treatment of denture material specimens by antibacterial soap “ClearaSept” and a reliable significant decrease in microbial and yeast adhesion after application of Protefix active cleaner solution, which demonstrates a more significant antimicrobial effect in comparison to “ClearaSept” against Staphylococcus aureus, Escherichia coli, and Candida albicans.

Sign in / Sign up

Export Citation Format

Share Document